web analytics
13.3 C
Munich
Sunday, September 25, 2022

Rushnet Inc (OTCMKTS: RSHN) Powerful Runner as Co Reports Record Revenues and Looks to Spinoff heliosDX

Rushnet Inc (OTCMKTS: RSHN) is rocketing up the charts up over 80% on Tuesday on over 400 million shares traded or about $1.2 million in dollar volume. The moves come as its subsidiary heliosDX continues to make big moves besides the revenues of $1.9 million for Q2, 2022. In the last few months, heliosDX has processed over 1,000 medically necessary physician ordered tests, and billed nearly one million dollars without reimbursement or substantiated justification. heliosDX expanded its Infectious Disease PCR panel to include the Human Monkeypox Virus. On Tuesday heliosDX launched its testing for the Human Monkeypox Virus through its partner laboratory. All of this is in line with the ambitious vision management has for the Company working on a number of major acquisitions to help grow the business to $50 million in revenue in three years.  

The rise in RSHN revenues comes from its fast-growing operating subsidiaries heliosDX and Grandeza Healthcare. heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. The Company is contracted in 44 of the lower 48 states and looking to expand its reach and capabilities. Management is looking to spin off heliosDX as a standalone Company with new shares in the Company distributed to current shareholders. Grandeza Healthcare is a healthcare billing and consulting company. Providing expert billing and coding services to laboratories, medical practices, dental offices, and other medical verticals.  RSHN has a long history of big moves running from current levels to at least $0.027, now that RSHN is moving northbound with power investors are jumping on board.  

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Rushnet Inc (OTCMKTS: RSHN) operating out of Orange Park, Florida has transformed over the past year into a revenue powerhouse with the acquisition of heliosDX; a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. heliosDX is contracted in 44 of the lower 48 states and looking to expand its reach and capabilities. Always staying ahead of the curve, by continually investing in its infrastructure with the most efficient scientific proven instruments, and latest cutting-edge software for patient and physician satisfaction. This allows heliosDX to provide physicians fast and accurate reporting meeting and exceeding industry benchmarks. The Company excels in patient and client care through physician designed panels that aid in testing compliance and reporting education. heliosDX as the first step to bring value to shareholders. The has company progressed in the last few months and plans future acquisitions to bolster company and shareholder value.  Rushnet currently operates as heliosDX and Grandeza Healthcare; a healthcare billing and consulting company. Providing expert billing and coding services to laboratories, medical practices, dental offices, and other medical verticals.  In addition to billing, Grandeza Healthcare provides Revenue Cycle Management (RCM) for all clients, as well as customized consulting services. Grandeza is a rapidly growing company adding new services and value to further demonstrate our competitive advantage.  

heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, and Infectious Disease (PCR). We are contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. The Company intends to always stay ahead of the curve by continually investing in our infrastructure with the most efficient scientific proven instruments and latest cutting-edge software for patient and physician satisfaction. In management’s opinion, following such best practices are intended to allow heliosDX to provide physicians fast and accurate reporting, meeting, and exceeding industry benchmarks. It is our goal to excel in patient and client care through physician designed panels that aid in testing compliance and reporting education. 

heliosDX is a revenue powerhouse that not only does significant sales but whose sales are growing at a rapid rate. During 2021 heliosDX did $5,893,984 in total revenues from Billing services and Laboratory testing fees. During Q2, 2022 heliosDX reported $1,977,761 in revenues putting the Company on track to generate over $7.5 million in annual revenues for 2022. Last year heliosdDX acquired a privately held laboratory with $10,000,000 annual revenues processing more than 5,000 tests monthly with a capacity of 12,000 monthly UDS tests. heliosDX and RushNet Inc. sign to acquire this laboratory gaining strategic benefits regarding location and contracting potential. heliosDX continues to search the market for additional laboratories for acquisition. A third laboratory has been identified and preliminary numbers shared, but negotiations have yet to begin.

According to a recent update from the Company, the Rushnet, Inc. of the past is long gone. However, remnants of its historical dealings still cling to the business that have posed challenges to current management as it navigates the public sector in pursuit of the long-term goals that we’ve set for the current Rushnet. Today, we have a completely new face, new management and new goals within the National Diagnostics Laboratory and the Healthcare Billing and Coding space which is operating today as heliosDX and Grandeza Healthcare. The services and objectives of today are completely different and have an ultimate goal of continuing the enhancement of shareholder value. As in life, a business can be presented with various paths to choose in order to stay the course and achieve its ultimate long-term vision. The company’s (heliosDX and Grandeza Healthcare) goals have not changed: grow the business to $50 million in revenue in three years and thereby increase shareholder value. The company has not wavered from this target and aims to accomplish this vision. The main primary target on this long-term path has been to acquire another toxicology laboratory that we know will greatly benefit the business and its shareholders.  

For the Inside Scoop on Rushnet Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RSHN

heliosDX Spinoff: Earlier this year RSHN announced the proposed Rushnet dividend of heliosDX shares planned to be issued upon the spinoff of heliosDX. This proposed structure is free of any dilution to Rushnet – no additional shares of RushNet will be consumed in the process – it will have the same number of shares outstanding as it does now. 

As part of the 15-month plan, Rushnet and its subsidiaries, heliosDX and Grandeza Healthcare, recently announced the completion of the PCAOB audit. This necessary and crucial step was needed in order to proceed with: (1) the issuance of dividend shares of the future heliosDX, Inc. to current RSHN shareholders and (2) the raising of $20,000,000 through the filing of a Tier 2, Regulation A with the SEC. Shares of heliosDX, not shares of RushNet, will be offered as part of the public offering.  

Through the public offering of heliosDX shares from the Regulation A, heliosDX plans to raise $20,000,000 for future business endeavors. These heliosDX shares to be distributed to RushNet shareholders as well as the fundraising element, are to be qualified by the Regulation A Offering to be free trading shares. For every six hundred and fifty (650) shares of RSHN owned, shareholders will receive one (1) share of heliosDX, Inc. 

heliosDX is doing big things besides the record revenues of $1.9 million for Q2, 2022. In the last few months, heliosDX has processed over 1,000 medically necessary physician ordered tests, and billed nearly one million dollars without reimbursement or substantiated justification. heliosDX has provided laboratory services to WellMed patients throughout the United States for years and recently WellMed initiated a bad faith scheme to not pay for valid, medically necessary laboratory tests ordered by licensed physicians on behalf of WellMed patients. As WellMed continues to receive premiums as an MCO, heliosDX will continue servicing these patients while fighting WellMed for physician, patient and laboratory rights. 

heliosDX also moves quickly; on Monday heliosDX reported it is expanding its Infectious Disease PCR panel to include the Human Monkeypox Virus. Due to the rising concern and surge of reported cases of the Monkeypox Virus in the United States, heliosDX is adding testing to its infectious disease panel immediately. Together with its lab partners the Company is responding to the growing need of testing to identify the virus accurately and in turn to allow physicians and clinics nationwide to effectively treat patients that are suffering. On Tuesday heliosDX launched its testing for the Human Monkeypox Virus through its partner laboratory effective today. 

https://twitter.com/StockTrader187/status/1557179054998130688

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $14 million market valuation the Company has 8,174,641,795 shares outstanding. While RSHN debt load may seem like a lot, the Company has serious potential and is executing at every level. The Company’s heliosDX and Grandeza Healthcare have seen significant growth since they were acquired and were responsible for $5,893,984 in total revenues in 2021 up more than double from 2020. helios alone has done $1.9 million in the last quarter. The stock got a boost after the Company reported in an update that the reverse split has been cancelled and the Company was working on a major acquisition to help grow the business to $50 million in revenue in three years. RSHN is currently under heavy accumulation and has legions of shareholders and a growing international following that are bidding the price higher in recent trading.  RSHN is under heavy accumulation and volume has picked up substantially as the stock looks to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension; a break over $0.0249 and its blue skies ahead. We will be updating on RSHN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with RSHN.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in RSHN either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.